Saudi Arabia Vaccines Market Overview, 2028

Saudi Arabia Vaccines Market Overview, 2028

The Kingdom of Saudi Arabia is a major donor and a key partner in international development. More than 95 developing countries in Asia, Africa and other regions of the world have benefitted from their aid. The Kingdom provides aid through different channels, mainly the Saudi Fund for Development, which acts as the major channel for economic and social development aid. In addition, the Kingdom contributes to multilateral, regional and international development funds such as the World Bank, the Arab Fund for Economic and Social Development, the Islamic Development Bank, and the OPEC Fund for International Development etc. The Kingdom is an advocate of humanitarian assistance providing aid for vaccination and matters such as the eradication of poverty, famine and polio amongst other important issues. The Saudi Ministry of Health is responsible for healthcare and vaccination programs in the country. Saudi Food and Drug Authority (SFDA) oversee the regulation and approval of vaccines and medicines in Saudi Arabia. They may provide information on approved vaccines and their distribution. To provide simple access for individuals, Saudi Arabia developed immunization centers across the nation, including hospitals, clinics, and mass vaccination sites. In order to speed up the vaccination procedure, drive-through vaccination facilities have been established in some cities. Saudi Arabia supported the purchase and distribution of vaccines by working with international organizations like the World Health Organization (WHO). Saudi Arabia has immunization requirements for a variety of endeavors, including travel and access to specific public areas.

According to the research report, “Saudi Arabia Vaccine Market Overview, 2028” published by Bonafide Research, the market is anticipated to reach more than USD 780 Million by 2028. The use of vaccines has increased significantly in Saudi Arabia, which has significantly boosted the country's overall vaccine market growth. There is a growing need for vaccines, which has been fueled by a number of factors. The Saudi government has made significant investments in healthcare facilities and has been vigilant in supporting vaccination initiatives. To make sure that vaccines are easily accessible to the populace, this includes the development of vaccination clinics and centers across the country. The corona pandemic has highlighted the value of immunization, and Saudi Arabia has joined other countries in their fight against the virus. A strong public awareness campaign and the government's quick rollout of COVID-19 vaccines have raised awareness of the importance of vaccines in the prevention and management of infectious diseases. The Saudi population is increasingly accepting of vaccines as a result of rising preventative healthcare awareness and the desire to shield oneself and loved ones against curable diseases. This mentality change has increased the demand for vaccines and contributed to the market's rapid expansion. Due to their active involvement in vaccine creation, distribution, and research, Saudi Arabia's pharmaceutical and medical sectors have also been crucial to this rise. International alliances and cooperation have made it possible for the nation to have access to a variety of vaccines, from common immunizations to specialty vaccines for tourists and expatriates.

In Saudi Arabia, the vaccine market in 2022 witnessed a notable dominance of conjugated vaccines, closely followed by recombinant vaccines. Conjugated vaccines, renowned for their effectiveness in preventing bacterial infections, particularly among infants and young children, held a significant share of the market. They have played a pivotal role in Saudi Arabia's vaccination programs, providing protection against diseases like Haemophilus influenzae type b (Hib) and pneumococcal infections. The success of conjugated vaccines can be attributed to their ability to stimulate a strong and lasting immune response. Simultaneously, recombinant vaccines emerged as a compelling choice in the Saudi Arabian market. These innovative vaccines, produced through genetic engineering techniques, have garnered attention due to their safety and precision. Recombinant vaccines are known for their ability to trigger targeted immune responses without the use of live pathogens, making them a preferred choice in situations where safety and accuracy are paramount. Their potential to address a range of infectious diseases, including hepatitis B, has made them an essential component of Saudi Arabia's vaccination landscape.

The market is divided into Monovalent and Multivalent Vaccines according to the type of vaccines. Some vaccinations (multivalent or polyvalent vaccines) need numerous antigens of the same disease or various pathogen serotypes/serogroups in combination to protect adequately. Both monovalent and multivalent vaccines are significant in the realm of immunization because they address several facets of disease prevention. Both forms of vaccines are essential for protecting the public's health, while many vaccination programs employ multivalent vaccines more frequently. Contrarily, monovalent vaccinations are made particularly to provide defense against a single illness or infection. They are valuable when dealing with diseases where the pathogen exhibits significant variations, or when targeting a specific health threat, such as a new emerging infectious disease or a disease with a complex structure. Monovalent vaccines offer precision in immunization, ensuring focused protection against a particular threat. The choice between multivalent and monovalent vaccines depends on several factors, including the epidemiology of the disease, the population's susceptibility, and the availability of effective vaccines. Both types contribute to the success of vaccination programs and the reduction of disease burden. Multivalent vaccines provide broad protection, while monovalent vaccines offer tailored defense when needed.

The market is divided into Hospital Pharmacy, Retail Pharmacy, Institutional Sales, and Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.) based on the distribution channels for vaccines. It is essential to maintain each vaccination at the prescribed storage temperature. For example, the majority of vaccines (all inactivated vaccines and live nasal spray influenza vaccine) should be kept in the refrigerator between 2° and 8°C (36° and 46°F). In vaccine storage units, temperature monitoring tools like thermometers or digital data recorders are employed. Because hospital pharmacies place a great priority on maintaining such conditions, their distribution has the biggest market share. A key improvement in public health is the expansion of vaccination availability in retail pharmacies. It improves accessibility, education, and convenience, which eventually results in higher vaccination rates and stronger community immunity against diseases that can be prevented. Given the growing importance of retail pharmacies in both healthcare delivery and public health activities, this trend is expected to continue.

Considered in this report:
• Geography: Saudi Arabia
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• Saudi Arabia Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology:
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:
• Paediatric Vaccines
• Adult Vaccines

By End-User:
• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.